

1 **Title:** Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium  
2 pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy:  
3 Results of an open-label, prospective, exploratory clinical study

4 **Running Title:** N-163 beta glucan as disease modifying agent in DMD

5 **Authors:**

6 Kadalraja Raghavan<sup>1,2,3</sup> ([drkraghavan@nichimail.jp](mailto:drkraghavan@nichimail.jp))

7 Vidyasagar Devaprasad Dedeepiya<sup>4</sup> ([drddp@nichimail.jp](mailto:drddp@nichimail.jp))

8 Subramaniam Srinivasan<sup>4</sup> ([masala76@gmail.com](mailto:masala76@gmail.com))

9 Subramanian Pushkala<sup>5</sup> ([pushkala66m@gmail.com](mailto:pushkala66m@gmail.com))

10 Sudhakar Subramanian<sup>6</sup> ([drsudhakar77@gmail.com](mailto:drsudhakar77@gmail.com))

11 Nobunao Ikewaki<sup>7,8</sup> ([nikewaki@phoenix.ac.jp](mailto:nikewaki@phoenix.ac.jp))

12 Masaru Iwasaki<sup>9</sup> ([miwasaki@yamanashi.ac.jp](mailto:miwasaki@yamanashi.ac.jp))

13 Rajappa Senthilkumar<sup>10</sup> ([rsk@nichimail.jp](mailto:rsk@nichimail.jp))

14 Senthilkumar Preethy<sup>10</sup> ([drspp@nichimail.jp](mailto:drspp@nichimail.jp))

15 Samuel JK Abraham<sup>4,9,11</sup> ([drsam@nichimail.jp](mailto:drsam@nichimail.jp))

16 **Affiliations:**

17 1. Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for  
18 Advanced Recovery and Education (JAICARE), Madurai, India

19 2. Department of Paediatric Neurology, Kenmax Medical Service Private Limited,  
20 Madurai, India.

21 3. Department of Paediatric Neurology, Sarvee Integra Private Limited, Chennai, India.

- 22 4. Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative  
23 Medicine (NCRM), Chennai, India.
- 24 5. Department of Immunology, The Tamil Nadu Dr. M.G.R. Medical University,  
25 Chennai, 600032, India.
- 26 6. Department of Anesthesia and Pain service, Toronto Western Hospital, 399 Bathurst  
27 street Toronto, Ontario, Canada.
- 28 7. Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
- 29 8. Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
- 30 9. Centre for Advancing Clinical Research (CACR), University of Yamanashi - School  
31 of Medicine, Chuo, Japan.
- 32 10. Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine  
33 (NCRM), Chennai, India.
- 34 11. Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu,  
35 Japan

36 **Corresponding author information:**

37 Dr. Samuel JK Abraham,

38 II Department of Surgery & CACR,

39 University of Yamanashi, Faculty of Medicine

40 Address for correspondence: 3-8, Wakamatsu, Kofu, 400-0866, Yamanashi, Japan

41 Email id- [drsam@nichimail.jp](mailto:drsam@nichimail.jp); Alternate email id: [drspp@nichimail.jp](mailto:drspp@nichimail.jp)

42 Fax: +81-55-235-7569

43

44

45 **Declarations:**

46 *Ethics approval and consent to participate*

47 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346.

48 Registered on 5th May, 2021. The study was approved by the Institutional Ethics Committee

49 (IEC) of Saravana Multispeciality Hospital, India on 12th April, 2021.

50 *Consent for publication*

51 Not applicable

52 *Availability of data and material*

53 All data generated or analysed during this study are included in the article itself.

54 *Funding*

55 No external funding was received for the study

*Competing interests*

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of novel beta glucans using different strains of *Aureobasidium pullulans* and also an applicant to several patents of relevance to these beta glucans.

56 *Authors' contributions*

57 KR, NI and SA. contributed to conception and design of the study. KR, RS and NI helped in

58 data collection and analysis. SA and SP drafted the manuscript. VD, SS, SUP, SSU and MI

59 performed critical revision of the manuscript. All authors read and approved the final

60 manuscript.

61

62

63 *Acknowledgements*

64 The authors would like to dedicate this paper to the memory of Mr. Takashi Onaka, who  
65 passed away on the 1st of June, 2022 at the age of 90 years, who played an instrumental role  
66 in successfully culturing an industrial scale up of AFO-202 and N-163 strains of  
67 *Aureobasidium pullulans* after their isolation by Prof. Noboru Fujii, producing the novel beta  
68 glucan described in this study.

69 They thank

70 1. The Government of Japan and the Prefectural Government of Yamanashi for a special  
71 loan and M/s Yamanashi Chuo Bank for processing the transactions.

72 2. Ms. Sunitha, Mr. Vincent, Mr. Shivakumar (Physiotherapist), Dr. Madhankumar and  
73 the staff of Kenmax & Sarvee Integra, for their assistance during the clinical study and data  
74 collection of the manuscript.

75 3. Fr. Francis Xavier, Fr. Vargheesh Antony, Fr. Marianathan and Mr Jeyachandran of  
76 JAICARE for their support during the clinical study.

77 4. Mr. Mitsuru Nagataki (Sophy Inc, Kochi, Japan), for necessary technical  
78 clarifications.

79 5. Mr. Yoshio Morozumi and Ms. Yoshiko Amikura of GN Corporation, Japan for their  
80 liaison assistance with the conduct of the study.

81 6. Loyola-ICAM College of Engineering and Technology (LICET) for their support to  
82 our research work.

83

84

85

86

87

88 **Abstract**

89 **Background:** This trial is to evaluate the effects of supplementation of Aureobasidium  
90 pullulans-N-163 strain produced 1,3-1,-6 beta glucan in young patients with Duchenne  
91 muscular dystrophy (DMD).

92 **Methods:**

93 Twenty-seven male subjects aged 5-19 years with DMD were included, nine in the control  
94 arm and 18 in the treatment arm to receive N-163 beta glucan along with conventional  
95 therapies for 45 days. While performing the analysis, patients were stratified into: those not  
96 administered steroids (Steroid -ve) (Control, n=5; treatment, n=9), those administered  
97 steroids (Steroid +ve) (Control, n=4; treatment, n=9), which was not pre-specified.

98 **Results:**

99 IL-6 showed a significant decrease in the N-163 Steroid -ve group, from  $7.2 \pm 1.2$  pg/ml to  
100  $2.7 \pm 0.03$  pg/ml. IL-13 decreased in both treatment groups—from  $157.76 \pm 148.68$  pg/ml to  
101  $114.08 \pm 81.5$  pg/ml (N-163 Steroid -ve) and from  $289.56 \pm 232.88$  pg/ml to  $255.56 \pm 214.13$   
102 pg/ml (N-163 Steroid +ve). TGF- $\beta$  levels showed a significant decrease in the N-163 Steroid  
103 -ve group. Dystrophin levels increased by up to 32% in both treatment groups. Medical  
104 research council (MRC) grading showed slight improvement in muscle strength improvement  
105 in 12 out of 18 patients (67%) in the treatment group and four out of nine (44%) subjects in  
106 the control group.

107 **Conclusion:**

108 Supplementation with the N-163 beta glucan food supplement produced beneficial effects: a  
109 significant decrease in inflammation and fibrosis markers, increase in serum dystrophin and

110 slight improvement in muscle strength in DMD subjects over 45 days, thus making this a  
111 potential adjunct treatment for DMD after validation.

112 **Trial registration:**

113 The study was registered in Clinical trials registry of India, CTRI/2021/05/033346.

114 Registered on 5th May, 2021.

115

116 **Keywords:** Duchenne muscular dystrophy; N-163; beta glucan; disease modifying agent;

117 inflammation; fibrosis; dystrophin

118

119

120

121

122

123

124

125

126

127

128

129 **Introduction:**

130 Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder  
131 causing severe and progressive weakness of skeletal muscles, leading to loss of ambulation  
132 along with concomitant impairment of cardiac and respiratory muscles and early mortality.  
133 Mutations in the dystrophin gene, which cause total loss of the dystrophin protein [2], remain  
134 the major underlying mechanism. Loss of dystrophin leads to damage of the myofibres'  
135 plasma membranes and distorts the structural stability of the plasma, leading to weakness in  
136 the myofibres. The weakened myofibres cannot withstand the contraction and relaxation  
137 cycles occurring during muscle function. The damage to the membrane releases the  
138 cytoplasmic contents, triggering the immune system and causing further muscle fibre  
139 damage, weakness and ultimately death [3]. A chronic proinflammatory state ensues, with  
140 neutrophil infiltration and macrophages' phagocytosis of the degenerated tissue [3],  
141 preventing repair of the muscle damage, which otherwise occurs in a highly orchestrated  
142 manner for faster repair in other physiological conditions. The muscle is relatively  
143 immunologically privileged, with a low capacity to generate localized immune responses and  
144 thus having low rates of abscess and granuloma formation [3]. Therefore, it becomes  
145 essential to modulate the inflammation and immunity to resolve the chronic inflammatory  
146 state in therapeutic approaches to DMD. Steroid therapy is the most commonly employed  
147 immuno-modulatory treatment approach. However, side effects include weight gain, weak  
148 bones, high blood pressure and behaviour changes in addition to muscle weakness and  
149 atrophy in the long term [4,5]. Thus, there arises the need to develop strategies that will assist  
150 in immunomodulation with lesser side effects. Nutritional supplements are a potential option.  
151 Beside beta glucans yielding locomotor improvement in zebrafish models of DMD [6], a 1-  
152 3,1-6 beta glucan from the N-163 strain of the black yeast *Aureobasidium pullulans* has been  
153 reported to mitigate inflammation, evident by decreases in anti-inflammatory markers such as  
154 CD11b, serum ferritin, galectin-3 and fibrinogen. It also produces beneficial immuno-

155 modulation via a decrease in the neutrophil-to-lymphocyte ratio (NLR) and an increase in the  
156 lymphocyte-to-CRP ratio (LCR) and leukocyte-to-CRP ratio (LeCR) in human healthy  
157 volunteers [7]. Mitigation of lipotoxicity-associated inflammatory cascades in a mouse study  
158 has also been reported [8]. Another study done in an animal model of non-alcoholic  
159 steatohepatitis (NASH) showed a decrease in liver inflammation and accumulation of F4/80+  
160 cells (macrophages associated with inflammation) [9] in the liver. The present exploratory  
161 study is to evaluate the immunomodulatory efficacy of the N-163 strain of *A. pullulans*-  
162 produced beta 1-3,1,6 glucan in comparison with a conventional therapeutic regimen in  
163 patients with DMD.

#### 164 **Methods:**

165 This trial was an investigator-initiated, single-centre, randomized, open-label, prospective,  
166 comparative clinical study of patients with DMD. The study was conducted over 45 days.  
167 The two treatment arms included were:

168 ***Treatment arm I***, control arm: Conventional treatment regimen comprising standard routine  
169 physiotherapy for joint mobility along with medications, viz., T. calcium and vit. D 1000  
170 with or without deflazacort (steroid) 6mg to 24 mg.

171 ***Treatment arm II***, intervention: One sachet of N-163 beta glucan (15g gel) once daily along  
172 with conventional treatment.

173 The stratification based on steroid was performed only during analysis of the data and was  
174 not pre-specified.

175 ***Inclusion criteria:*** Male subjects with molecular diagnosis of DMD aged 6-18 years who  
176 were willing to participate in the study with written informed consent.



177 **Exclusion criteria:** Patients with a previous (within the past 1 month) or concomitant  
178 participation in any other therapeutic trial; a known or suspected malignancy; any other  
179 chronic disease or clinically relevant limitation of renal, liver or heart function according to  
180 the discretion of the investigator.

181 **Investigations:**

182 The following tests were carried out after written consent was obtained from the study  
183 subjects.

184 **At baseline and at the end of the study (after 45 days):**

- 185 • Background survey: gender, date of birth, age, habits, current medical history,  
186 medication, treatment, allergies (to drugs and food), regular use of food for specified  
187 health uses, functional foods, health foods, intake of foods rich in  $\beta$ -glucan foods  
188 containing beta-glucan and intake of immunity-boosting foods
- 189 • Medical history and physical measurements: height, weight, BMI, temperature
- 190 • Physiological examination: systolic blood pressure, diastolic blood pressure, pulse  
191 rate
- 192 • ECG
- 193 • Muscle strength test using MRC grading [10]
- 194 • Six-minute walk test (6MWT) [11]
- 195 • North Star Ambulatory Assessment (NSAA) [12]
- 196 • Blood sampling and investigations for the levels of IL-6, IL-13, TGF- $\beta$ , creatinine  
197 kinase (CK), titin, haptoglobin, TNF- $\alpha$ , dystrophin, cystatin in the blood and  
198 myoglobin in the urine
- 199 • Subjects were contacted every week for drug compliance and recording of adverse  
200 effects, if any

201

202 ***Study subjects = 28***

203 The study was designed as an exploratory study, so there were two intervention conditions:  
204 one control and one test group. As the minimum number of participants required for  
205 statistical comparisons within and between intervention conditions is four per intervention  
206 condition, a total of 28 target study participants (10 in treatment arm I [control] group and 18  
207 in treatment arm II [N-163]) were used. One patient was disqualified due to misrepresentation  
208 of diagnosis. The CONSORT flow diagram of the trial is shown in Figure 1.

209 ***Selection of study subjects***

210 Study investigators and other investigators included study subjects who had consented to  
211 participate in the study, met the selection criteria and not the exclusion criteria, and who were  
212 judged to have no problem participating in the study.

213 ***Allocation of study subjects***

214 The person in charge of the allocation, as specified in the study protocol, allocated the study  
215 subjects to the two groups by simple randomization (1:2).

216 ***Primary outcome:***

217 Observation of changes in the levels of IL-6 in serum and myoglobin levels in urine from the  
218 baseline measured by ELISA.

219 ***Secondary outcome:***

- 220 • Observation of changes in the levels of IL-13, TGF- $\beta$ , CK, titin, dystrophin,  
221 haptoglobin and cystatin C in the serum measured by ELISA.  
222 • Observation of changes in the muscle function tests

- 223 • Monitoring for adverse effects

#### 224 ***ELISA:***

225 The biomarkers were validated using sandwich enzyme immunoassay. ELISA kits were  
226 purchased from different manufacturers and the assay details along with sensitivity are listed  
227 in Table 2. ELISAs were performed according to manufacturer's instructions and the serum  
228 was diluted to fall within the linear range of each respective assay.

#### 229 ***Statistical analysis:***

230 All data were analysed using Excel statistics package analysis (Microsoft Office Excel) and  
231 Origin2021b software. All 27 randomized participants were included in safety and efficacy  
232 analysis sets. All statistical tests were performed at a significance level of 0.05 without  
233 correction for multiple comparisons or multiple outcomes. Non-parametric tests such as  
234 Mann-Whitney U test and Kruskal-Wallis tests were used.

235

#### 236 **Results:**

237 Twenty-eight patients were screened and 27 were randomized to control (n = 9) and treatment  
238 (n = 18). One patient was disqualified due to misrepresentation of diagnosis. The CONSORT  
239 flow diagram of the trial is shown in Figure 1.

240 Demographics are shown in Table 1.

241 The stratification of patients was as follows based on steroid administration during analysis:

242 Group I: Control group (n = 9);

243 A. Steroids not administered (n = 5) (Steroid -ve)

244 B. Steroids administered (n = 4) (Steroid +ve)

245 Group II: Treatment (N-163) group (n = 18);

246 A. Steroids not administered (n = 9) (Steroid -ve)

247 C. Steroids administered (n = 9) (Steroid +ve)

248 The mean  $\pm$  SD age for the total study population was  $11.18 \pm 3.86$  years (range 5-19 years).

249 The mean age across the groups were Control (Steroid-ve) -14.25 years; Control (Steroid  
250 +ve) – 13.6 years; N-163 (Steroid -ve) – 9.6 years; N-163 (Steroid +ve) – 11.87 years.

251 However the difference was not statistically significant (P= 0.316). The mean  $\pm$  SD body  
252 weight was  $35.59 \pm 15.5$  kgs (range = 10 to 65 kgs).

253 No adverse events were reported. No clinically significant changes from baseline data were  
254 observed on physical examination or in vital signs—temperature, blood pressure, oxygen  
255 saturation, pulse rate or ECG (data not shown).

256 ***Biomarker levels:***

257 Levels are expressed as mean  $\pm$  SD. In regard to the primary outcome, IL-6 showed decrease  
258 in both the control and the treatment groups. However, when the analysis was stratified for  
259 steroid administration, IL-6 showed the highest decrease in the N-163 Steroid -ve group,  
260 from a baseline value of  $7.2 \pm 1.2$  pg/ml to  $2.7 \pm 0.03$  pg/ ml post intervention and the  
261 difference was significant (p-value = 0.01) (Figure 2, 6).

262 IL-13 increased in both control groups—from  $300.4 \pm 114.5$  pg/ml at baseline to  $550.732 \pm$   
263  $107.95$  pg/ml post-intervention in the Steroid -ve group and from  $142 \pm 112.82$  pg/ml at  
264 baseline to  $263.5 \pm 99.38$  pg/ml post-intervention in the Steroid +ve group. It decreased in  
265 both the treatment groups—from  $157.76 \pm 148.68$  pg/ml at baseline to  $114.08 \pm 81.5$  pg/ml  
266 post-intervention and from  $289.56 \pm 232.88$  pg/ml at baseline to  $255.56 \pm 214.13$  pg/ml post-  
267 intervention. The difference was statistically significant (p-value = 0.006) (Figure 3, 6).

268 TGF- $\beta$  levels showed a significant decrease in the N-163 Steroid -ve group, from a baseline  
269 value of  $3302 \pm 1895$  pg/ml to  $1325.66 \pm 517$  pg/ml post intervention, which was  
270 significantly lower than all the other groups (p-value = 0.02) (Figure 4, 6).

271 Dystrophin levels showed a significant increase in the N-163 Steroid -ve group, from a  
272 baseline value of  $3.01 \pm 1.58$  ng/ml to  $4.01 \pm 1.44$ ng/ml post intervention, and the N-163  
273 Steroid +ve group went from a baseline value of  $3.15 \pm 2.43$  ng/ml to  $3.78 \pm 2.17$  ng/ml post  
274 intervention, which was significantly higher than the control groups (p-value = 0.0009)  
275 (Figure 5, 6). The N-163 Steroid -ve group showed higher dystrophin expression than the N-  
276 163 Steroid +ve group with the difference being significant (p-value = 0.01). The percentage  
277 increase in dystrophin levels in the treatment group was up to 32.8%.

278 Haptoglobin did not show much difference pre or post intervention in the treatment groups,  
279 but it was marginally increased in the control group (Figure 7). CK increased in the treatment  
280 groups (Figure 7). Urine myoglobin increased in the N-163 Steroid +ve group but decreased  
281 in all the other groups (Figure 7).

282 Titin and cystatin C decreased in the N-163 Steroid +ve group and the control Steroid +ve  
283 group, but the difference was not significant. TNF- $\alpha$  decreased in all the groups except the N-  
284 163 Steroid -ve group (Figure 7).

285 The 6MWT and NSAA did not show any significant differences between the groups (Figure  
286 8). The MRC grading showed slight improvement in 12 out of 18 patients (67%) in the  
287 treatment group and only four out of nine (44%) subjects in the control group but it was not  
288 statistically significant (p-value = 0.02) (Table 3, Figure 8).

## 289 **Discussion:**

290 Current interventions for DMD, such as corticosteroids and rehabilitative care, help to  
291 prolong survival up to the third or the fourth decade of life. Corticosteroids remain the

292 mainstream supportive approach to slow inflammation and the associated decline in muscle  
293 strength and function [4]. However, steroids have their own adverse effects, and their  
294 prescription is based on risk versus benefit to that specific patient and tolerance to the  
295 medication. Exon-skipping gene therapy and cell-based strategies to replace the mutant DMD  
296 gene are in development, but the desired outcome has not yet been achieved. In the  
297 meantime, nutraceuticals can be considered potential strategies for immune modulation and  
298 alleviating inflammation, as they are safer with lesser adverse effects [4]. Improvement of the  
299 locomotor performances and mitochondrial respiration by 1,3-1,6 beta-glucans in zebra fish  
300 model of muscular dystrophy [6] has already been reported.

301 In the current study, we focussed on a 1-3,1-6 beta glucan from the N-163 strain of the black  
302 yeast *A. pullulans* that has been reported to mitigate inflammation, evidenced by a decrease  
303 in anti-inflammatory markers and production of beneficial immuno-modulation [6-8]. The  
304 safety profile of N-163 beta glucan has been confirmed by the results.

305 **Anti-inflammatory and anti-fibrotic outcomes:** Circulating IL-6 is chronically elevated in  
306 individuals with DMD [13], which has been reported to contribute to DMD-associated  
307 cognitive dysfunction. IL-6 blockades have been advocated as a therapeutic approach for  
308 DMD [14]. In the present study, IL-6 showed highest decrease in the N-163 Steroid -ve group  
309 (Figure 2). While IL-6 is an acute inflammatory biomarker [14], IL-13 is a pro-fibrotic  
310 biomarker [15] and was significantly decreased (Figure 3). Together with the TGF- $\beta$   
311 pathway, it is a major proinflammatory and pro-fibrotic cytokine responsible for the chronic  
312 inflammatory response leading to replacement of the muscle by scar tissue or fibrosis,  
313 resulting in muscle weakness and loss of muscle function [16]. IL-6 values matched that of  
314 healthy controls and DMD patients who were treated with corticosteroids [17]. TGF- $\beta$  levels  
315 also showed a significant decrease in the N-163 Steroid -ve group (Figure 4). Dystrophin  
316 restoration of 20% expression [18,19] is considered the point of efficacy for a DMD therapy

317 [20] and was found to increase by 32.8% in both the treatment groups (Figure 5) of the  
318 present study from baseline. We used serum dystrophin evaluation as recent evidence points  
319 to the fact that the lack of dystrophin in the smooth muscle of blood vessels is the major  
320 contributing factor to skeletal muscle pathogenesis in DMD and not the dystrophin deficiency  
321 in skeletal or cardiac muscle [21]. Dystrophin is expressed in the tunica media of blood  
322 vessels, especially in the muscular arteries. It has also been reported that the blood vessel-  
323 associated dystrophin is encoded by another gene than the skeletal muscle dystrophin gene  
324 [22]. In a mdx mice model study, it was shown that dystrophin which was absent in the blood  
325 vessels could be restored by induced genetic expression of full-length human dystrophin (h-  
326 dys) and this expression was able to restore the NO-dependent attenuation of  $\alpha$ -adrenergic  
327 vasoconstriction in the exercising muscles, preventing further exacerbation of muscle fibre  
328 necrosis [23]. In the present study, an increase in the plasma levels of dystrophin, which must  
329 have been derived from vascular smooth muscle is evidence for the efficacy of beta glucans  
330 as a potential adjunct to restore dystrophin in DMD.

331 **Other biochemical markers of relevance:** While haptoglobin and urine myoglobin did not  
332 show significant differences, the increase in urine myoglobin in the N-163 Steroid +ve group  
333 deserves more analysis concerning the underlying mechanism. Greater activity among  
334 steroid-treated individuals may place their dystrophin-deficient muscles under greater  
335 mechanical stress, predisposing them to further muscle fibre damage and consequent  
336 myoglobinuria [24]. While titin and cystatin C decreased in the N-163 steroid +ve group and  
337 in the control Steroid +ve group, there was an increase in CK, which is paradoxical, as  
338 reports suggest that titin concentration correlates significantly with serum CK concentration  
339 [25].

340 **Muscle strength evaluation:** There were three evaluations to assess muscle strength and  
341 tone, done in a blinded manner by the same physiotherapist at baseline and post intervention.

342 Though the 6MWT and NSAA did not show any significant differences between the groups,  
343 MRC grading showed improvement of muscle strength in 67% of the subjects in the  
344 treatment group compared to 44% subjects in the control group, which is significant. The  
345 limitation of this being a 45-day study is relevant to the muscle-strength and functional  
346 evaluations, mandating the need for a longer study and follow-up duration. However, though  
347 small, the improvement in MRC grading at 45 days could be again attributed to the immune  
348 modulation effects of this disease-modifying supplement. The study shows proof of concept  
349 that DMD could be tackled by the N-163 beta glucan from three aspects: decrease in  
350 inflammation shown by decreased IL-6 and TNF- $\alpha$ , decrease in fibrosis evident by decreased  
351 TGF- $\beta$  and IL-13 and, more importantly, restoration of dystrophin evident from a 32.8%  
352 increase in dystrophin levels. These effects hold regardless of the use or non-use of steroids,  
353 which is important, as this safety-proven food supplement can help DMD patients regardless  
354 of steroid status.

355 Chronic inflammation being common to pathogenesis of all muscular dystrophies,  
356 immunomodulatory treatment may benefit patients with diverse types of muscular dystrophy  
357 [26]. Further, modulating the inflammatory response and inducing immunological tolerance  
358 to de novo dystrophin expression is critical to the success of dystrophin-replacement  
359 therapies [27]. The need to evaluate the muscles involved in respiratory function and  
360 myocardium should be mentioned here, as they are the cause of mortality in most of the  
361 DMD patients [1]. Though other dystrophies, such as limb girdle muscular dystrophy  
362 (LGMD), do not involve respiratory or cardiac muscles, inflammatory overactivity is the  
363 common pathophysiology among types of muscular dystrophy [26]. Once proven efficacious  
364 for DMD, extending the beneficial application of the N-163 beta glucans to other dystrophies  
365 such as LGMD can be considered.

366



367 DMD is a rare genetic disease with a maximum life expectancy of up to fourth decade, with  
368 the majority of victims dying in their late twenties to thirties. The average lifespan at birth,  
369 which was 20+ years for those born in or before 1970, has gradually increased by 10~15  
370 years for those born and diagnosed with DMD in the 1980s and 1990s. This increase is  
371 attributed to better or early ventilatory assistance, steroid usage and cardiac care [28,29],  
372 which are only supportive interventions. With the gene therapies approved recently, there is a  
373 hope of additional progress and increase in lifespan [30]. Though these gene therapies (such  
374 as exon skipping) address the root cause by splicing out selected exons from the pre-mRNA  
375 at or next to the mutation site, generating a translatable transcript from the mutant dystrophin  
376 gene leading to dystrophin expression [30, 31], they are still marred by challenges such as  
377 delivery of gene-editing components throughout the musculature and mitigation of possible  
378 immune responses [32]. The current need, therefore, is to modulate the immune system and  
379 control the inflammation and ensuing fibrosis to delay the progression of the disease. The  
380 earlier usage of steroids in a regular manner was later changed to intermittent usage [33] with  
381 regimens varying between institutes; now, newer steroids with lesser adverse effects are in  
382 various stages of progress towards clinical applications [34]. In this background, the safety of  
383 this N-163-produced beta glucan food supplement without adverse reactions is to be  
384 considered an indispensable value addition. Targeting the inflammation component (the  
385 criteria for selecting this supplement for this study) having yielded beneficial outcomes,  
386 additional studies on this characteristic could be of value to possibly extending their  
387 application for other neuroinflammatory diseases, such as multiple sclerosis.

388 The limitations of the study include uneven distribution of subjects, broad age range (5-19  
389 years) and short follow-up (only 45 days); improvements in muscle function over the course  
390 of the study showed variability that may have been due to the level of sensitivity to change of  
391 functional assessments during the disease progression in the age group. Among the 27

392 subjects, two-thirds were ambulatory and the remaining non-ambulatory; the evaluation  
393 criteria differences must be kept in mind, which may show equivalent quantification among  
394 all DMD patients at different stages of disease severity when non-invasive myograms to  
395 measure the individual muscles accurately could be undertaken. Further, the steroid dose was  
396 not uniform and fell into a broad range (6-24 mg). Also, the consumption of steroids vs those  
397 who did not consume them or those who had stopped steroids after an initial duration of  
398 consumption, as well as regimen variation, are to be considered while interpreting the  
399 outcomes. All these aspects mandate the need for larger randomized clinical trials of longer  
400 duration to validate this supplement as a treatment.

401 **Conclusion:**

402 N-163 beta glucan with and without steroids helped decrease IL-6, TGF- $\beta$  and IL-13 and  
403 increase dystrophin levels along with improvement of muscle strength in subjects with DMD  
404 in this clinical study. Thus, N-163 beta glucan is a safe and effective potential therapeutic  
405 adjunct for patients with DMD. While the benefits documented may help slow the rate of  
406 progression of this devastating disease, confirmation by longer and larger studies will help  
407 establish this agent for routine clinical application as a disease-modifying agent with the  
408 potential to help prolong the lifespan of DMD patients. After such validation, extending its  
409 application to other dystrophies such as LGMD could be considered, and further in-depth  
410 research in neuroinflammatory diseases are likely to shed light on the mechanism of action,  
411 leading to additional beneficial applications.

412

413

414

415

416

417

418

419 **Abbreviations:**

420 DMD: Duchenne muscular dystrophy

421 CK: Creatinine kinase

422 TNF- $\alpha$ : tumour necrosis factor - Alpha

423 MRC: Medical research council

424 NLR: Neutrophil-to-lymphocyte ratio

425 LCR: Lymphocyte-to-CRP ratio

426 LeCR: Leukocyte-to-CRP ratio

427 NASH: Non-alcoholic steatohepatitis

428 6MWT: Six-minute walk test

429 NSAA: North Star Ambulatory Assessment

430 LGMD: Limb girdle muscular dystrophy

431

432 **References:**

433 1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, Jones

434 K, Krishnamurthi R, Feigin V. Prevalence of muscular dystrophies: a systematic

435 literature review. *Neuroepidemiology*. 2014;43(3-4):259-68.

436 2. Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D.

437 Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a

438 multicenter, randomized, placebo-controlled, double-blind phase 3 trial. *Trials*.

439 2019;20(1):637.

- 440 3. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield  
441 LM, Woodcock J. Immune-mediated pathology in Duchenne muscular dystrophy. *Sci*  
442 *Transl Med.* 2015;7(299):299rv4.
- 443 4. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for  
444 Duchenne muscular dystrophy. *Cochrane Database Syst Rev.* 2004;(2):CD003725.
- 445 5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Spotlight on  
446 Research: Optimizing Steroid Treatment for Duchenne Muscular Dystrophy  
447 [https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-](https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-treatment-duchenne-muscular-dystrophy)  
448 [treatment-duchenne-muscular-dystrophy](https://www.niams.nih.gov/newsroom/spotlight-on-research/optimizing-steroid-treatment-duchenne-muscular-dystrophy) (Accessed: December 13, 2021).
- 449 6. Licitra R, Marchese M, Brogi L, Fronte B, Pitto L, Santorelli FM. Nutraceutical  
450 Screening in a Zebrafish Model of Muscular Dystrophy: Gingerol as a Possible Food  
451 Aid. *Nutrients.* 2021;13(3):998.
- 452 7. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R,  
453 Preethy S, Abraham SJK. Immune and metabolic beneficial effects of Beta 1,3-1,6  
454 glucans produced by two novel strains of *Aureobasidium pullulans* in healthy middle-  
455 aged Japanese men: An exploratory study. *medRxiv* 2021.08.05.21261640; doi:  
456 10.1101/2021.08.05.21261640
- 457 8. Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan  
458 M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK. Beneficial effects of the AFO-  
459 202 and N-163 strains of *Aureobasidium pullulans* produced 1,3-1,6 beta glucans on  
460 non-esterified fatty acid levels in obese diabetic KKAY mice: A comparative  
461 study. *bioRxiv* 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
- 462 9. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya VD, Vaddi S,  
463 Senthilkumar R, Levy GA, Abraham SJK. Hepatoprotective effects of *Aureobasidium*  
464 *pullulans* derived Beta 1,3-1,6 biological response modifier glucans in a STAM-

- 465 animal model of non-alcoholic steatohepatitis. bioRxiv 2021.07.08.451700; doi:  
466 10.1101/2021.07.08.451700
- 467 10. MRC Muscle Scale. [https://mrc.ukri.org/research/facilities-and-resources-for-](https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/)  
468 [researchers/mrc-scales/mrc-muscle-scale/](https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-muscle-scale/) (Accessed: December 13, 2021).
- 469 11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL,  
470 Atkinson L, Reha A, Hirawat S, Miller LL. The 6-minute walk test as a new outcome  
471 measure in Duchenne muscular dystrophy. *Muscle Nerve*. 2010;41(4):500-10
- 472 12. Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F;  
473 North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a  
474 functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.  
475 *Physiother Res Int*. 2012;17(2):101-9. doi: 10.1002/pri.520.
- 476 13. Stephenson KA, Rae MG, O'Malley D. Interleukin-6: A neuro-active cytokine  
477 contributing to cognitive impairment in Duchenne muscular dystrophy? *Cytokine*.  
478 2020;133:155134.
- 479 14. Mammen AL, Sartorelli V. IL-6 Blockade as a Therapeutic Approach for Duchenne  
480 Muscular Dystrophy. *EBioMedicine*. 2015;2(4):274-5.
- 481 15. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano AL, Muñoz-  
482 Cánoves P. Aberrant repair and fibrosis development in skeletal muscle. *Skelet*  
483 *Muscle*. 2011;1(1):21.
- 484 16. Ceco E, McNally EM. Modifying muscular dystrophy through transforming growth  
485 factor- $\beta$ . *FEBS J*. 2013;280(17):4198-209.
- 486 17. Pelosi L, Berardinelli MG, De Pasquale L, Nicoletti C, D'Amico A, Carvello F,  
487 Moneta GM, Catizone A, Bertini E, De Benedetti F, Musarò A. Functional and  
488 Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor  
489 Blockade. *EBioMedicine*. 2015 Feb 26;2(4):285-93.

- 490 18. Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda S, Yokota T, Aoki Y.  
491 Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of  
492 Therapeutic Approaches. *J Pers Med*. 2019;9(1):1.
- 493 19. Mendell JR, Rodino-Klapac L, Sahenk Z, Malik V, Kaspar BK, Walker CM, Clark  
494 KR. Gene therapy for muscular dystrophy: lessons learned and path forward.  
495 *Neurosci Lett*. 2012;527(2):90-9.
- 496 20. Wells DJ. What is the level of dystrophin expression required for effective therapy of  
497 Duchenne muscular dystrophy? *J Muscle Res Cell Motil*. 2019 ;40(2):141-150.
- 498 21. Gajendran, N. The root cause of Duchenne muscular dystrophy is the lack of  
499 dystrophin in smooth muscle of blood vessels rather than in skeletal muscle per se  
500 *F1000Research* 2018 ; 7: 1321.
- 501 22. Augier N, Boucraut J, Léger J, Anoaï M, Nicholson LV, Voelkel MA, Léger JJ,  
502 Pellissier JF. A homologue of dystrophin is expressed at the blood vessel membrane  
503 of DMD and BMD patients: immunological evidence. *J Neurol Sci*. 1992  
504 Feb;107(2):233-8.
- 505 23. Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki  
506 M, Araki K, Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T. Smooth  
507 muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice.  
508 *Hum Mol Genet*. 2006 Jul 15;15(14):2266-75.
- 509 24. Awano H, Matsumoto M, Nagai M, Shirakawa T, Maruyama N, Iijima K, Nabeshima  
510 YI, Matsuo M. Diagnostic and clinical significance of the titin fragment in urine of  
511 Duchenne muscular dystrophy patients. *Clin Chim Acta*. 2018;476:111-116.
- 512 25. Garrod P, Eagle M, Jardine PE, Bushby K, Straub V. Myoglobinuria in boys with  
513 Duchenne muscular dystrophy on corticosteroid therapy. *Neuromuscul Disord*. 2008  
514 ;18(1):71-3.

- 515 26. Raimondo TM, Mooney DJ. Anti-inflammatory nanoparticles significantly improve  
516 muscle function in a murine model of advanced muscular dystrophy. *Sci Adv.*  
517 2021;7(26):eabh3693.
- 518 27. Thomas GD, Ye J, De Nardi C, Monopoli A, Ongini E, Victor RG. Treatment with a  
519 nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse  
520 model of Duchenne muscular dystrophy. *PLoS One.* 2012;7(11):e49350.
- 521 28. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M,  
522 Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular  
523 dystrophy: an evidence review. *Orphanet J Rare Dis.* 2017;12(1):79
- 524 29. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, Perrouin Verbe B.  
525 Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM  
526 Yolaine de Kepper centre between 1981 and 2011. *Ann Phys Rehabil Med.*  
527 2013;56(6):443-54.
- 528 30. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular  
529 Dystrophy. *Mol Ther.* 2018;26(10):2337-2356.
- 530 31. Echevarría L, Aupy P, Goyenvalle A. Exon-skipping advances for Duchenne  
531 muscular dystrophy. *Hum Mol Genet.* 2018;27(R2):R163-R172.
- 532 32. Dzierlega K, Yokota T. Optimization of antisense-mediated exon skipping for  
533 Duchenne muscular dystrophy. *Gene Ther.* 2020;27(9):407-416. doi: 10.1038/s41434-  
534 020-0156-6.
- 535 33. Olson EN. Toward the correction of muscular dystrophy by gene editing. *Proc Natl*  
536 *Acad Sci U S A.* 2021;118(22):e2004840117.
- 537 34. Kourakis S, Timpani CA, Campelj DG, Hafner P, Gueven N, Fischer D, Rybalka E.  
538 Standard of care versus new-wave corticosteroids in the treatment of Duchenne

539 muscular dystrophy: Can we do better? *Orphanet J Rare Dis.* 2021;16(1):117. doi:  
540 10.1186/s13023-021-01758-9.

541 35. Boziki MK, Kesidou E, Theotokis P, Mentis AA, Karafoulidou E, Melnikov M,  
542 Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in Multiple  
543 Sclerosis; Where Are We, What We Know and Do Not Know. *Brain Sci.*  
544 2020;10(4):234.

545 36. Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G,  
546 Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK. Beneficial  
547 reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-  
548 producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism  
549 and potentials in neurodegenerative diseases. *medRxiv* 2021.10.26.21265505; doi:  
550 10.1101/2021.10.26.21265505

551

552

553

554

555

556

557

558

559

560

561



562

563

564

565

566

567

568

569

570

571 **Tables and Figures**

572 Table 1: Demographics and baseline characteristics

	Subject	Age in years	Weight in kgs	Exon Deletion	Clinical Diagnosis	Ambulatory/ Non-Ambulatory	Dose of Deflazacort (mg/day)	Duration of consumption of steroids
Control Steroid -ve	1	6-10	12	10 & 11	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	2	6-10	27	46-55	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	NA	NA
	3	16-20	48		Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	11-15	60	8 to 48	Duchenne Muscular Dystrophy	Non-Ambulatory	NA	NA

					(DMD)			
	5	11-15	55	10-11/Dup	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	NA	NA
Control Steroid +ve	1	16-20	65	44	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	6	8 years
	2	6-10	25	5 & 6	Duchenne Muscular Dystrophy (DMD)	Ambulatory	12	2.5 months
	3	6-10	21	49-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	9	11 months
	4	11-15	48	52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	6 years
N-163 Steroid -ve	1	6-10	28	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	2	1-5	10	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	3	11-15	38	45-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
	4	6-10	45	60	Becker muscular dystrophy (BMD)	Ambulatory	NA	NA
	5	6-10	39	10-11/Dup	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	NA	NA
	6	6-10	21	49-52	Duchenne Muscular	Ambulatory	NA	NA

					Dystrophy (DMD)			
	7	11-15	39	43	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	NA	NA
	8	11-15	40		Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	NA	NA
	9	6-10	22	44-57/Dup	Duchenne Muscular Dystrophy (DMD)	Ambulatory	NA	NA
N-163 Steroid +ve	1	1-5	18	48-50	Duchenne Muscular Dystrophy (DMD)	Non-Ambulatory	6	5 months
	2	11-15	59	17	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	2 months
	3	11-15	40	60	Becker muscular dystrophy (BMD)	Ambulatory	6	6 years
	4	6-10	20	48-52	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years
	5	6-10	36	48-50	Duchenne Muscular Dystrophy (DMD)	Ambulatory	6	3 years

573

574

575

576

577

578

579

580

581

582

583

584

585

586 Table 2: Details of the ELISA kits along with their sensitivity

<b>S.No</b>	<b>Human Antibody</b>	<b>Purchased from</b>	<b>Catalogue No.</b>	<b>Limit of detection/Sensitivity</b>
1	Interleukin-6 (IL6)	Seimens	10995080	3.0 pg/mL
2	Myoglobin	Diagnostic Automation Inc	1667-18	270 pg/mL
3	Dystrophin (DMD)	KINESISDx	K12-1446	0.042 ng/mL
4	Titin (TTN)	Mybiosource	MBS762344	0.094 ng/mL
5	Creatinine Kinase (CK)	Agappe	51404001	2.0 U/L
6	IL-13	Diaclone	850080048	1.5 pg/mL
7	TGF- $\beta$	Diaclone	650010096	8.6 pg/mL
8	Cystatin C	Siemens	E0001V	0.06 $\mu$ g/L
9	TNF-a	Siemens	LKNF1	6.23 pg/mL
10	Haptoglobin	Seimens	OSAV09	0.26 ng/mL

587

588

589

590

591

592

593

594

595

596

597

598

599 Table 3: Medical research council (MRC) grading of muscle power in the study groups

Subject	Ambulatory/Non-ambulatory	Baseline	Post-intervention	Progression
<b>Control group</b>				
1	Ambulatory	151	165	Improved
2	Ambulatory	133	162	Improved
3	Non-ambulatory	70	80	Improved
4	Non-ambulatory	164	164	No change
5	Non-ambulatory	109	106	Worsened
6	Non-ambulatory	102	105	Improved
7	Non-ambulatory	117	115	Worsened
8	Non-ambulatory	110	109	No change
9	Non-ambulatory	105	102	Worsened
<b>Treatment Group</b>				
1	Ambulatory	134	133	Worsened
2	Ambulatory	146	163	Improved
3	Ambulatory	119	131	Improved
4	Ambulatory	127	136	Improved
5	Ambulatory	154	160	Improved
6	Ambulatory	158	168	Improved
7	Non-ambulatory	102	119	Improved
8	Non-ambulatory	116	117	Improved
9	Non-ambulatory	127	127	No change
10	Non-ambulatory	120	131	Improved
11	Non-ambulatory	96	107	Improved
12	Non-ambulatory	111	122	Improved

13	Non-ambulatory	117	113	Worsened
14	Non-ambulatory	108	108	No change
15	Non-ambulatory	103	107	Improved
16	Non-ambulatory	145	148	Improved
17	Non-ambulatory	93	119	Improved
18	Non-ambulatory	Test couldn't be performed		

600


601

602

603

604


605 Figures:



606

607 Figure 1: CONSORT flow diagram of the trial

608



609


610 Figure 2: IL-6 showed the most significant decrease in the N-163 Steroid -ve group compared

611

to other groups. (\*p-value significance < 0.05)




612



613

614 Figure 3: Levels of IL-13 levels showed statistically significant increase in control groups  
615 and decrease in treatment groups (\*p-value significance < 0.05)


616



617

618 Figure 4: Levels of TGF-β showed significant decrease in the N-163 Steroid -ve group  
619 compared to other groups (\*p-value significance < 0.05)

620




621

622 Figure 5: Levels of dystrophin showed significant increase in the N-163 Steroid -ve group

623 compared to other groups (\*p-value significance < 0.05)


624



625

626 Figure 6: Comprehensive figure of IL-6, IL-13, TGF-β and Dystrophin showing comparison  
 627 of values between control and treatment group (N-163), pre- and post-intervention (\*p-value  
 628 significance < 0.05)

629




630

631 Figure 7: Levels of Creatinine kinase (CK), Titin, Cystatic-C, Urine myoglobin, Haptoglobin

632 and TNF- $\alpha$  between control and treatment group (N-163), pre- and post-intervention (\*p-  
633 value significance < 0.05)

634

635



636

637 Figure 8: MRC muscle grading, 6MWT and NSAA results between control and treatment

638 group (N-163), pre- and post-intervention (\*p-value significance < 0.05)

639

640

641